IBAB cites strong H1 growth and reaffirms EBIT guidance
IBAB says H1 growth and profitability were driven by Proton Therapy, reaffirming its EBIT guidance.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.